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ABSTRACT
Induction of specific cellular transitions is of clini-
cal importance, as it allows to revert disease cellu-
lar phenotype, or induce cellular reprogramming and
differentiation for regenerative medicine. Signalling
is a convenient way to accomplish such transitions
without transfer of genetic material. Here we present
the first general computational method that system-
atically predicts signalling molecules, whose per-
turbations induce desired cellular transitions. This
probabilistic method integrates gene regulatory net-
works (GRNs) with manually-curated signalling path-
ways obtained from MetaCore from Clarivate Ana-
lytics, to model how signalling cues are received
and processed in the GRN. The method was ap-
plied to 219 cellular transition examples, including
cell type transitions, and overall correctly predicted
experimentally validated signalling molecules, con-
sistently outperforming other well-established ap-
proaches, such as differential gene expression and
pathway enrichment analyses. Further, we validated
our method predictions in the case of rat cirrhotic
liver, and identified the activation of angiopoietins
receptor Tie2 as a potential target for reverting the
disease phenotype. Experimental results indicated
that this perturbation induced desired changes in the
gene expression of key TFs involved in fibrosis and
angiogenesis. Importantly, this method only requires
gene expression data of the initial and desired cell
states, and therefore is suited for the discovery of
signalling interventions for disease treatments and
cellular therapies.
INTRODUCTION
Cellular phenotypes can be characterized by stable gene ex-
pression profiles maintained by the underlying gene regula-
tory networks (GRNs). Conversions between different cel-
lular phenotypes (i.e. cellular transitions) can be induced
either by perturbing directly GRNs, or cellular signalling
pathways that in turn act onGRNs. These transitions range
from cell type conversion events (reprogramming, differen-
tiation), to conversions between cellular phenotypes within
a cell type, due to drug treatment or disease conditions. The
induction of desired cellular transitions is of clinical inter-
est, as it allows to revert cellular disease phenotypes to their
healthy counterparts, or to derive required cells and tissues
for cell replacement therapies. By doing so without trans-
fer of genetic material, but rather acting on signalling path-
ways, the safety concerns currently posed by gene therapy
protocols can be overcome (1).
In order to systematically identify signalling perturba-
tions induced by small molecules that are able to trigger
changes in cellular phenotype, the effect of signalling on
gene expression must be modeled. In this regard, two broad
classes of computational methods have been recently de-
veloped, namely GRN-free and GRN-based approaches.
Some of the GRN-free methods compare a signature gene
list from the query gene expression profile with a com-
pendiumof signatures associatedwith known perturbations
(2–4). Another set of GRN-free methods maps gene ex-
pression onto signalling pathways, and identifies the path-
ways or sub-pathways whose activities are (dys)regulated by
using enrichment measures (5,6). Although these methods
have been applied to identify signalling pathways perturba-
tions inducing gene expression changes, they lack the mech-
anistic understanding of how a change in TF expression or
activity gives rise to a new cellular phenotype. Thus, to cap-
ture how signalling can induce cellular transitions, a model
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that integrates signalling and gene regulatory networks is
required. Existing GRN-based methods use ordinary dif-
ferential equations (ODEs) to model the expression level
of each gene as a function of the expression of its regula-
tors (7–9). Nevertheless, ODE-basedmodelling frameworks
cannot be applied to systems where only a small number of
transcriptomics samples is available, as they require a large
amount of data for parameter estimation. Various studies
have presented manually-curated models where signalling
and gene regulatory networks have been integrated to study
individual cellular transitions (10–12). However, we are not
aware of any computational approach that systematically
integrates and models the signalling and transcriptional
regulatory layers without requiring a large amount of gene
expression data.
Here, we introduce a computational method that predicts
signalling molecules whose perturbation can induce tran-
sitions between cellular phenotypes, given their initial and
target gene expression profiles. This approach integrates the
signalling network with a Boolean transition-specific GRN
model. A central role in this model is played by interface
TFs, which connect the two regulatory layers. The signalling
information transmitted along pathways results in the acti-
vation or inhibition of interface TFs, which then act on the
GRN, triggering cellular transitions. In line with previous
observations (13,14), the transmission of signalling infor-
mation is modeled as a probabilistic event depending on
protein availability. Indeed, preliminary results show that
the pathways predicted with this approach were enriched
in proteins differentially phosphorylated upon perturba-
tion, supporting their involvement in the signal transduc-
tion. Further, signalling molecules were ranked according
to how effectively they act on the interface TFs that can in-
duce the desired cellular phenotype. Importantly, by consid-
ering changes in the GRN initial state upon interface TFs
perturbations, this method is able to model how signalling
cues are received and processed in the GRN to give rise to
the desired phenotype. To our knowledge, this mechanistic
insight is not provided by other general methods.
We applied our method to 219 cellular transition exam-
ples, including the induction of cellular differentiation and
reprogramming, and obtained correct predictions in the
majority of them. Importantly, this method showed bet-
ter performance than well-established GRN-free methods,
and similar performance to another GRN-based method
(DeMAND), while requiring substantially less data. Fi-
nally, the method was applied to the prediction of signalling
molecules for the reversion of cirrhotic liver to its healthy
counterpart. Experimental results confirmed that the ac-
tivation of one of the predicted candidates restored the
healthy expression state of key TFs involved in cirrhosis.
In summary, here we propose the first general method, to
our knowledge, which uses gene expression data to identify
signalling molecules able to induce cellular transitions. The
low data requirements make this tool readily applicable to
the design of new experimental protocols and the discovery
of signalling perturbations for disease treatment or cellular
therapies.
MATERIALS AND METHODS
Perturbation targets
Mapping of drugs and small molecules to their direct pro-
tein targets was carried out using STITCH (http://stitch.
embl.de/ (15), v5.0, accessed in October 2017, with ex-
perimental evidence confidence >0.4); DrugBank (www.
drugbank.ca (16), accessed in October 2017) andMetaCore
from Clarivate Analytics were used to specify the effect (ac-
tivation, inhibition, unknown effect). For growth factors
and proteins, the interacting proteins were obtained from
STITCH (same selection criteria), and the signalling net-
work retrieved fromMetaCore was used to define the effect
on the targets.
Datasets
All datasets contained in the Connectivity Map (build
02, (17)) and generated on Affymetrix Human Genome
U133A 2.0Arraywere processed.We alsomanually selected
from ArrayExpress microarray experiments where expres-
sion data was collected before and after the application of a
single perturbation, prioritizing non-cancer cell lines and, in
particular, experiments related to cell differentiation or re-
programming. Datasets were discarded if all the targets of
the used perturbation were either absent from the signalling
network, or not connected to interface TFs by a directed
path. In addition, experiments with chemically undefined
perturbations (e.g. serum, oxygen, co-culturing conditions
etc.) were also discarded. The evaluation was restricted to
datasets with selective perturbation, meaning the number of
target signallingmolecules present in the signalling network
was ≤30. These criteria allowed us to test our method on
the prediction of well-characterized and specific signalling
perturbations. The considered datasets contain expression
values before and a few hours after the perturbation (6 h
after drug application for CMap, and up to 48 h after the
last perturbation in the manually selected datasets). In re-
programming examples, gene expression data from primary
cells for both the initial and the desired cellular states was
used.
Phosphoproteomics datasets
Studies where a single perturbation was applied and quan-
tified through phosphoproteomics data were paired to gene
expression datasets matching the initial and final conditions
as closely as possible. Ideally, the same cell type was per-
turbed with the same chemical, and gene expression was
measured with comparable delay after perturbation. When
this was not possible, time after perturbation was allowed
to change up to 48 h. In addition, we considered closely re-
lated cell lines and different chemical compounds targeting
the same protein targets. Regarding quantitative phospho-
proteomics data, the list of differentially phosphorylated
proteins were obtained from the original papers; when not
available, we repeated the analysis as described in them (see
Table 1). We used the highest fold change observed for any
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phosphosite on a protein as the fold change of that whole
protein.
Prior knowledge networks
Signalling network. We retrieved 75 canonical signalling
pathways present in MetaCore from Clarivate Analytics in
July 2017, and merged them together in a single signalling
network, composed of 2496 nodes and 6876 edges. InMeta-
Core, all edges are obtained by expert manual curation of
full text papers from literature, directed and signed when
possible; the nodes represent signalling entities, either sin-
gle proteins or complexes that act as functional entities. We
removed edges corresponding to ‘Technical’ or ‘Unspeci-
fied’ effect, and ‘Technical’, ’Transcriptional Regulation’,
‘Influence onExpression’, ‘Catalysis’ and ‘Transport’ mech-
anisms. Some TFs are known to act as complexes but are
represented in MetaCore as separate functional nodes all
interacting with the same targets. We checked the litera-
ture supporting all the interactions involving these TFs, and
manually removed the ones where the interaction did not
specifically involve the TF considered, but other compo-
nents of the complex (see Supplementary Table S1 for list
of pathways used and the list of manually removed edges).
Transcriptional regulatory interactions. For transcrip-
tional regulatory interactions, we considered all interac-
tions among human TFs and transcriptional regulators
as listed in Animal TFDB 2.0 (18), that are labelled in
MetaCore as ‘Transcriptional regulation’, ‘Influence on
Expression’ and ‘Regulation’, with ‘Activation’, ‘Inhibition’
or ‘Unspecified’ effect (accessed in March 2017).
Microarray data processing
All data was processed starting from raw CEL files with
the same pipeline, consisting of normalization with frozen-
RMA (R package fRMA (19)) and assignment of expres-
sion state by Gene Expression Barcode (20,21). Briefly, the
barcode approach assumes that the distribution of normal-
ized, log-transformed expression values for a specific probe-
set observed across multiple tissues, cell types and condi-
tions, can be fitted with a mixture model of a Gaussian dis-
tribution corresponding to non-expressed values, and a uni-
form distribution corresponding to expressed values (20).
We selected for each gene the probeset with highest vari-
ance, then given this model, we assigned Boolean state 1
(expressed) to TFs that had probability lower than 0.05 of
belonging to the non-expressed distribution (corresponding
to parameter cutoff = 0.95 in the pipeline), and state 0 oth-
erwise. Furthermore, in this work we defined the expression
probability of a probeset x as the ratio:
p (x) =
1
2 fe(x)
1
2 fe(x) + 12 fn(x)
where fe is the probability density function (pdf) of x in
the uniform distribution U(μ, 15), and fn is the pdf of
x in N(μ, σ ) (see Supplementary Information and Sup-
plementary Figure S1). To each protein, we assigned the
maximum probability of expression found across all repli-
cates. The values μ and σ were calculated and distributed
in (21) and are available as R Bioconductor packages for
microarray platforms Affymetrix Human Genome U133A,
Affymetrix Human Genome U133 Plus 2.0, Affymetrix
Human Genome U133A 2.0, Affymetrix Human Gene
1.0 ST Array, Affymetrix Mouse Gene 1.0 ST Array and
Affymetrix Mouse Genome 430 2.0 Array. While relying on
pre-processed expression value distributions limits the ap-
plication of our method to these specific microarray plat-
forms, it also reduces the requirement for data samples to
one sample per cellular state, one for the initial and one for
the required state.
Gene regulatory network (GRN) inference
TFs that were assigned different Boolean state (1 = ex-
pressed, 0 = not expressed) before and after the perturba-
tion are assumed to also have differential activity in the two
cellular states. These TFs were connected in a gene reg-
ulatory prior-knowledge network. This Boolean network
was pruned so that the resulting GRN matches the ini-
tial and final Booleanized gene expression states, as de-
scribed in (22). Briefly, this algorithm assumes that both
states are represented by a separate point attractor in the
Boolean network state space, and removes edges from the
initial network in order tomake the attractor states compat-
ible with the Booleanized gene expression profiles. Datasets
with GRNs containing <10 connected TFs after the prun-
ing were excluded from further analysis, as we observed that
they tend to correspond to perturbations affecting biologi-
cal processes different from signalling (e.g. metabolic reac-
tions, structural proteins).
Addition of TFs connecting signalling pathways and GRN
The activity of signallingmolecules on theGRN ismediated
by the TFs that belong to signalling pathways and there-
fore can act as signalling effectors (interface TFs). TFs that
are not expressed initially will require some time to be ex-
pressed, and are not likely to be involved in the signalling
response. Additionally, we assumed that whatever signal is
applied to the cell, it initially travels to the nucleus using
proteins that are already expressed in the cell. Therefore, in
this study we defined interface TFs as TFs that regulate TFs
present in the GRN (GRN-TFs), are expressed at the ini-
tial time point, and are connected through expressed sig-
nalling paths to any of the source nodes (0-indegree nodes)
of canonical signalling pathways. No further filtering was
applied (Supplementary Figure S2).
In silico perturbations of interface TFs
The interface TFs that are more likely to drive the cells from
the initial to the final gene expression profile were found
by in silico perturbations of the initial GRN state. We ex-
haustively tested combinations of up to four interface TFs
at the same time, by fixing their Boolean state and updat-
ing synchronously the Boolean state of the network follow-
ing a majority (threshold) logic rule until it converged to
a fixed-point attractor. Interface TFs have the property of
being directly regulated by signalling events, meaning that
their expression at the initial cellular state is not sufficient to
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Table 1. Datasets for which both phosphorylation and gene expression data is available. Gene expression datasets are indicated with their GEO accession
number
Gene expression datasets (GEO
access ID)
Dataset Cell type Perturbation
Phosphorylation
study (PMID)
LFC
cutoff for
DP control treated
Gnad et al., 2016 HCT116 cells MAPK inhibition
[GDC0973 (1uM)]
27273156 log2(3) GSM455560 GSM455565
Wilkes et al., 2015 MCF7 cells EGFR inhibition
[EGFR2]
26060313 1 GSM149914 GSM149941
Rudolph et al., 2016 MCF7 cells EGF 28009266 2.38 GSM325937 GSM325958
GSM325959
Sharma et al., 2014 HeLa cells EGF 25159151 1 GSM156764 GSM156770
D’Souza et al., 2014 HaCaT cells TGF 25056879 1 GSM297456 GSM297458
Wierer et al., 2013 MCF7 cells estradiol 23770244 log2(1.5) GSM289651 GSM289654
GSM289652 GSM289655
GSM289653 GSM289656
The same log fold change values used in the original studies were used to define differential phosphorylation.
assume they are also active or inactive. Unless an interface
TF had different Boolean states between the initial and fi-
nal gene expression, its activity state at the initial time point
was unknown. Therefore, we simulated the network state by
assigning it both 0 and 1 states.
The perturbations are ranked according to their flipping
score, which is the number of GRN-TFs that change their
state after simulation. We then selected the combinations
of interface TFs that obtained the three best (including
ties) flipping scores (best performing combinations, BPCs).
This corresponds to parameter best = 3 in the pipeline. We
removed the combinations of interface TFs that did not
show any synergistic effects (i.e., combinations whose flip-
ping TFs were the same as the union of flipping TFs of
individual constituent interface TFs). This is because our
method aims to prioritize candidate signalling molecules
that specifically target interface TFs over those that target a
large number of interface TFs, in order to avoid unspecific
effects on cells upon their perturbations. Prioritizing inter-
face TFs that synergistically maximize the flipping score al-
lows us to select BPCs with fewer, but more specific, inter-
face TFs that need to be targeted by optimal signalling per-
turbations (Supplementary Figure S3). Datasets for which
the best flipping score did not represent at least 40% of the
GRN-TFs were discarded from further analysis.
Probability of intermediate signalling molecules regulating
interface TFs
We approximated the regulation of signalling molecule x on
interface TF y by considering the most probably expressed
path (MPP) connecting x to y. The probabilityMx,y of the
MPP is defined as:
Mx,y = p
(
MPPx→y
) = max p (x → . . . → y)
where p (x → . . . → y) =∏ j∈proteins∈simple path p( j ) and
p(j) is the expression probability of the intermediate sig-
nalling molecule j. We used two variations of this approach
(see Supplementary Information and Supplementary Fig-
ure S4):
• Proteins belonging to the same functional modules tend
to show transcriptional correlation (23). Accordingly, we
calculated the Pearson correlation coefficient of expres-
sion values across all the processed datasets inCMap, and
we increased the probability of interactions among pro-
teins that were correlated at the expression level (absolute
correlation > 0.7 and sign of correlation matching the
sign of the interaction).We used these corrected probabil-
ities to identify the MPPs and calculate their correlation-
corrected probability.
• We expect that the longer the path used to reach an inter-
face TF (measured in number n of interactions present in
the path), the higher the chances that crosstalk and non-
functional interactions occur. Therefore, the probability
of the MPP connecting between each signalling protein
and interface TF was multiplied by e−n (24), resulting in
what we defined as length-corrected probability.
The distribution of probabilities Px from the same sig-
nalling protein x to all interface TFs was obtained by:
Px,y = Mx,y∑
i∈inter f aceTFs Mx,i
Two Px vectors exist for each molecule, one correspond-
ing to correlation-corrected probability, and one length-
corrected probability. Finally, we determined the sign of
each MPP by
signx,y =
∏
e=edges∈MPP sign (e)
If the sign is positive, the activation (inhibition) of x
causes the activation (inhibition) of TF y with probabil-
ity Px,y. If the sign is negative, activation (inhibition) of x
causes inhibition (activation) of y with probability Px,y.
Prediction of candidate signalling proteins for gene expres-
sion state transitions
We assumed that a high frequency of a particular
activated/inhibited interface TF among the BPCs is a good
indication that it consistently has large effects on the GRN
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state. For each state assigned to each interface TF (TFs-
state pair s) the frequency Fs in all BPCs was calculated as:
Fs = ksk
where k is the total number of BPCs and ks is the number
of combinations where s is present. The frequencies across
all TF-state pairs S were then normalized to sum up to one,
giving the probability distribution Q:
Q = Fi∑
i∈S Fi
The ranking of the signalling molecules was obtained by
comparing their probability of reaching the interface TFs
(Px) with the frequency of such TFs in the BPCs (Q) by
Jensen-Shannon divergence:
JSD (Px ‖ Q) = 12 D (Px ‖ M) +
1
2
D (Q ‖ M)
where M = 12 (Px + Q) and D (X ‖ Y) =
∑
i X(i )log
X(i )
Y(i )
(Kullback–Leibler divergence). Both activation and inhibi-
tion of the signalling protein x are possible, but their scores
differ because the sign of the paths connecting x to the in-
terface TFs will be opposite, resulting in different effects on
theGRN state. For example, assume that the activation of x
results in the activation of TF y, which is frequently present
in the BPCs. The inhibition of x on the other hand, assigns
to y the inactive state, which is not present in the BPCs.Here
the activation of x would have a better score than its inhibi-
tion, because while the probability of reaching TF y is the
same, the resulting perturbations on the GRN have differ-
ent effectiveness in changing its state.
The signalling molecules were ranked by JSD values (the
smaller the better), and then assigned a rank:
R (x) = min
v∈Px
rank (x, v)
where R(x) is the rank assigned to signalling molecule x,
and is defined as the minimum rank obtained by x using
either correlation- or length-based Px variant (v).
A cut-off was defined as a fraction (from 1 to 10%) of
the maximum R value present in the final ranking. The sig-
nalling molecules whose rank R was lower than the cut-off
were considered candidate drivers of the transition between
initial and final states. For single perturbation datasets,
the prediction was considered successful if at least one
of the direct targets of the experimental perturbation ap-
peared among the candidates, as was also done in (25). At
each cut-off, the chance of obtaining at least one pertur-
bation target (i.e. a success) in a randomly selected set of
the same size was calculated by one-sided hypergeometric
test. The optimal cut-off was selected as the one where our
method showed the maximum improvement from the ran-
dom chance, across the datasets coming from CMap.
Functional analysis
GO biological process terms enrichment was calculated
separately for candidate and non-candidate signalling
molecules using the R package gProfilerR. The overlap be-
tween GO terms associated to experimental perturbation
targets (target terms) and enriched terms was counted for
each dataset and the distributions of these values were com-
pared by one-sided Wilcoxon test.
The distances on the signalling network topology were
calculated from all signalling molecules to experimental
perturbation targets, and in the opposite direction. The di-
rection with shorter distance was then selected, and the av-
erage distance from one signalling molecule to all the reach-
able experimental perturbation targets was calculated. The
distributions of average distances from candidate and non-
candidate signalling molecules were compared byWilcoxon
test with 100 000 Monte Carlo replicates (P-value < 0.05).
Experimental model of cirrhosis and CVX-060 treatment
To induce cirrhosis, 10 male Wistar rats were exposed to in-
halation of CCl4, as previously described (26) and accord-
ing to the criteria of the investigation and ethics commit-
tee of the Hospital Clı´nic Universitari and the University
of Barcelona. Five cirrhotic rats were treated once a week
with 10 mg/kg of CVX-060 (Pfizer, Inc., New York, NY,
USA) for 4 weeks. CVX-060 was diluted in 500 l of saline
solution and injected intravenously via the tail vein.
Prediction of signalling molecules for reversion of cirrhotic
state
Expression data for healthy liver in male Wistar rats was
obtained from GEO dataset GSE71201. Gene expression
in CCl4 and CCl4+CVX-060 treated livers was quantified
using Affymetrix GeneChip Rat Genome 230.2 Array. Af-
ter quality control and PCA visualization, two replicates for
each treatment were retained for further analysis. Each gene
was assigned gene expression probability equal to 1− p,
where p is the P-value obtained from Affymetrix MAS5.0
detection call. A gene was considered expressed if its expres-
sion probability was equal or larger than 0.94 (correspond-
ing to call ‘marginal’ or ‘present’ from MAS5.0).
The prediction of GRN state after CVX-060 treatment
was obtained by first selecting all the interface TFs in the
BPCs that are activated/inhibited with probability higher
than zero by the activation of Tie2. Then, the BPCs com-
posed only of such TFs are selected, and the GRN-TFs that
change their state in any of these BPCs are expected to flip
when CVX-060 is applied. The same GRN state is also ob-
tained when predicting the effect of the inhibition of Ang2
on the GRN state.
Comparison with previously published methods
Differential gene expression. Differential gene expression
between the initial and query expression profiles was cal-
culated with the R package limma. Genes with absolute
log fold change (lfc) >log2(1.5) and BH-adjusted P-value
<0.05 were considered differentially expressed. When repli-
cates were not available, the lfc cut-off alone was applied.
MetaCore pathway enrichment was calculated by one-sided
hypergeometric test (BH-adjusted P-value < 0.05). To rank
all signallingmolecules according to differential expression,
they were ordered by decreasing absolute lfc values.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/advance-article-abstract/doi/10.1093/nar/gkz232/5428308 by Antonio del Sol on 05 April 2019
6 Nucleic Acids Research, 2019
SPIA. Differentially expressed genes (DEGs) were se-
lected by BH-adjusted P-value <0.1, or by lfc >log2(1.5) if
replicates were not available. The R package SPIA (27) was
used to calculate KEGG signalling pathways significantly
perturbed. A prediction was considered successful if any of
the significant pathways contained any of the direct targets
of the perturbation applied in a dataset. Datasets without
any DEG were discarded.
Connectivity Map. DEGs were selected by BH-adjusted
P-value <0.05, or by lfc >log2(1.5) if replicates were not
available. Up to 150 up- and down-regulated genes, by de-
creasing absolute lfc, were submitted to the ‘Batch query’
functionality of CMap L1000 query, accessible at https:
//clue.io/l1000-query#batch (28), with sig fastgutc tool op-
tion enabled. The summary results across cell lines were
used for further analysis. The predictions were considered
correct if the experimental perturbation, its direct targets,
or a drug targeting the perturbation targets were assigned a
connectivity score (tau) >90. Datasets with <10 DEGs, or
raising errors during the submission, were discarded from
the analysis.
DeMAND. Our method was applied to the GEO datasets
used as part of the benchmarking for DeMAND (termed
GEO13 in the original paper)(29). Only datasets generated
on Affymetrix whole-transcriptome array platforms were
considered. When available, values μ and σ (21) were used
to calculate the probability of expression; otherwise, the
Affymetrix MAS5.0 detection call was used as previously
described. Perturbation targets from STITCH, DrugBank,
as well as the original paper, were used to define successful
predictions. In DeMAND, genes with FDR≤.1 were con-
sidered predicted candidates.
RESULTS
Method overview
We present here a computational method that predicts sig-
nalling molecules, including plasmamembrane receptors or
intermediate signalling proteins, whose perturbations can
induce desired cellular transitions. It requires only gene ex-
pression profiles of the initial and desired cellular states, and
does not require a large number of replicates, time-series ex-
pression profiling, or phosphoproteomics data. Therefore,
this method can be applied to the transition between any
pair of initial and query cell states, including novel cellular
transitions that have not been achieved previously.
In the first step of the pipeline, the activity of TFs is ap-
proximated byBooleanizing their expression state. TFswith
differential activity are selected and connected to form a
Boolean transition-specific GRN. In this framework, the
cellular states are modelled as network state attractors re-
sulting from the same network topology. The objective is to
induce the transition from the initial to the desired attrac-
tor by acting on TFs that are regulated by signalling inter-
actions (i.e. interface TFs). Perturbations of these interface
TFs are performed exhaustively to identify the ones that are
most effective for the GRN state transition (Figure 1A).
In the next step, we predict the effect of the
activation/inhibition of each molecule in the signalling
network on the downstream interface TFs. Signal transduc-
tion is an inherently stochastic process, strongly dependent
on post-translational protein modifications not captured
by gene expression data (30). However, it has been shown
that the response to signalling perturbations changes across
different cell types depending on the abundance of specific
signalling proteins prior to perturbation (13,14). Thus,
we model signal transduction as a probabilistic process
driven by protein availability, which can be estimated
from gene expression data, an approach followed also by
other methods (31,32). We define the probability of signal
transduction from a signalling molecule to interface TFs
as the product of the expression probability of all proteins
present in the MPP between them. Two variants of the
signalling probability are used: (a) the probability of an
interaction is higher if the genes involved are correlated
in gene expression, since their proteins are more likely to
work as a functional unit (23); (b) the probability of a path
is multiplied by the exponential of its length, to account for
the number of interactions required for the signal to reach
the TFs (i.e. the longer, the less probable). The sign of each
MPP is then incorporated into its outcome, i.e. if the overall
sign of a path is positive, the activation/inhibition of that
path will activate/inhibit the target interface TF, whereas
if the overall sign is negative, the activation/inhibition of
that path will inhibit/activate the target TF (Figure 1B).
Finally, our method ranks each signalling molecule in the
network based on the Jensen-Shannon divergence of the
probability P, with which it acts on interface TFs, from the
likelihood Q of the interface TFs themselves of changing
the GRN state (Figure 1C).
Phosphoproteomics datasets suggest that MPPs are used in
signal transduction
While not all proteins are subject to phosphorylation, many
signalling pathways rely on phosphorylation cascades for
transmitting the signal in the cytoplasm. Therefore, phos-
phoproteomics experiments allow the inference of protein
activity during a signalling event (33). Proteins showing dif-
ferential phosphorylation upon perturbation are expected
to be transmitting the newly applied signal, and therefore
the signalling paths used for signal transduction should
show an enrichment in differentially phosphorylated pro-
teins compared to the paths that are not used for signal
transduction. Given this assumption, we asked if the MPPs
selected by ourmethodwere enrichedwith phosphorylation
events.
To investigate this, we gathered experiments for which
both gene expression and quantitative phosphoproteomics
data were acquired before and after a specific perturbation
was applied (Table 1). In each of the datasets, the direct tar-
get molecules of the experimental perturbation and the in-
terface TFs that they can affect via signalling were identi-
fied, and the MPP between each pair of perturbation tar-
get molecule and interface TF was computed (Figure 2A).
While a protein might contain multiple phosphosites, not
all of them are necessarily functional. However, at the mo-
ment, only a limited number of proteins have their phos-
phosites functionally characterized, and for the majority of
the proteins this information is not available (33). There-
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Figure 1. Ranking signalling molecules according to their likelihood of inducing desired changes in GRN state. (A) The gene regulatory network (GRN)
containing differentially Booleanized TFs is connected to interface TFs. The initial state is perturbed by in silico simulation of fixed states of up to four
interface TFs at the same time. The best performing combinations (BPCs) are selected as the ones having the top three flipping scores (including ties). The
frequency of each interface TF state (activated +, inhibited –) is calculated and then normalized to give the probability distribution Q of each TF state of
causing changes in the GRN state. (B) The expression probability of each protein is mapped onto the signalling network and used to define the probability
of signalling interactions. For each signalling molecule X the most probably expressed paths (MPPs) connecting it with all interface TFs are selected. The
probability and the sign of the MPPs are calculated, and combined to give the probability distribution P of activating or inhibiting the interface TFs by
activating or inhibiting X. Both correlation-based and length-based probabilities are calculated (see Methods). (C) The probability distributions Q and P
are compared through Jensen-Shannon divergence (JSD). The score is used to rank the perturbations of each signalling molecule. The best ranking that
each molecule obtains across the correlation-based and length-based rankings defines its final rank. A fraction of the final ranking is selected.
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Figure 2. Enrichment of MPPs in differentially phosphorylated (DP) pro-
teins. (A) MPPs are defined by correlation-based and length-based proba-
bilities. For both of thesemethods, the fraction ofDPproteins in eachMPP
for each target-interface TFpair is compared by t-test to other simple paths
connecting the same pair. (B) Average fraction ofMPPs per datasets signif-
icantly enriched in DP proteins compared to alternative simple paths con-
taining DP proteins (P-value < 0.05). (C) Breakdown of the single MPPs.
Orange: number of interface TFs for which the fraction of DP proteins
in the MPP is significantly higher than in other simple paths. Light-blue:
the difference is not significant; grey: there are noDP proteins in any of the
paths connecting the perturbation target to interface TFs. The same results
were obtained with both correlation-based and length-based MPPs.
fore, we first considered a protein differentially phospho-
rylated (DP) if any of its phosphosites showed differential
phosphorylation, defined in the original studies (see Table
1). We then calculated the frequency of DP proteins in the
MPP, and in randomly selected simple paths among the
same initial and final nodes (up to 100 randomly selected
paths, limited to maximum path length = 10 edges, Figure
2A). The difference between the frequency of DP proteins
in the MPP and the random paths was tested for statisti-
cal significance (t-test, P-value < 0.05). In each dataset, the
majority of the MPPs had significantly more DP proteins
than other possible paths, for both probability computa-
tion methods we used to define MPPs (Figure 2B and C).
Therefore, the MPPs between signalling molecules and in-
terface TFs reasonably captured phosphorylation patterns
observed shortly after signalling perturbations. This gave
us confidence in using MPPs as biologically relevant paths
used by signal transduction.
Prediction of signalling molecules that induce desired gene
expression change
We applied ourmethod to datasets belonging to CMap gen-
erated on Affymetrix Human Genome U133A 2.0 Array,
plus datasets manually selected from ArrayExpress. After
quality controls, 219 datasets (193 from CMap, 26 fromAr-
rayExpress) were used for the analysis. For each dataset,
a GRN was built and perturbed in silico to obtain BPCs.
General characteristics ofGRNs andBPCs are summarized
in Supplementary Information and Supplementary Figure
S5. In order to generate the final signalling molecule rank-
ing, a) the probability with which each signalling molecule
can act on interface TFs, and b) the likelihood of the inter-
face TFs to induce the desired GRN state transitions, are
compared using Jensen-Shannon divergence (see alsoMeth-
ods). Signalling molecules that specifically reach a few well-
performing interface TFs will score better than molecules
which indistinctly act on many interface TFs. On average,
∼1400–1500 signalling molecules are present twice in the
final ranking, once for their activation and once for their
inhibition, resulting in approximately 2900–3000 potential
perturbations for each dataset.
First, we compared the ranking obtained with our
method with one based on differential gene expression. Or-
dering genes by their log fold change did not prioritize per-
turbation targets, which were found only after selecting a
big portion of the ranking, while our method performed
better (see Figure 3A). For example, to retain a correct
experimental perturbation in at least 50% of the datasets,
858 molecules need to be selected by log fold change, com-
pared to the 239 required by ourmethod. This confirms that
proteins involved in signal transduction do not necessarily
show differential expression, and therefore more complex
approaches are needed in order to obtain better predictions
using gene expression data.
We considered a prediction correct if at least one of the
known perturbation targets appeared in the top ranked
molecules. The success rate was calculated as the fraction
of datasets for which the prediction was correct. Different
ranking cut-offs were tested, and for all of them, the suc-
cess rate on CMap datasets was better than the random
selection of the same number of candidates (Figure 3B).
Cut-off = 0.06 was used for subsequent analysis because
our method showed the highest performance gain at this
cut-off with respect to the random success rate, with 136
out of the total 219 datasets (62%) being successful (Sup-
plementary Table S2). In particular, it correctly predicted
at least one perturbation target in 115/193 CMap exam-
ples (60%, versus random success of 41%, Figure 3B and
C), 6/10 datasets for non-cancer cell lines selected from Ar-
rayExpress, 5/6 datasets with matched phosphoproteomics
data (Table 1), and 10/10 cell type transitions datasets (dis-
cussed below). We observed that our method is particu-
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Figure 3. Method performance. (A) Fraction of datasets where at least
one target is correctly predicted, across an increasing selection of sig-
nalling molecules. Proteins are ranked according to their expression log
fold change between the initial and final gene expression profile (DEG),
or according to our method. (B) Variation of success rate and number of
selected signalling molecules, at different ranking cut-offs. Circles = ob-
larly successful in predicting signalling molecules for cellu-
lar transitions where a higher number of differentially ex-
pressed genes exists between the initial and desired cellular
states. This suggests that acting on the GRNwith signalling
perturbations can be an effective strategy, especially for cel-
lular transitions requiring broad changes in gene expression
(Supplementary Figure S6).
The number of direct targets of a compound or protein
influences the probability of finding at least one of them
among the selected candidates. Therefore, we divided the
datasets in different classes based on the number of tar-
gets reported for the corresponding perturbation. For each
of these classes, the performance of our method was com-
pared to the frequency with which at least one real target
is expected to appear in random sets of signalling proteins
of the same size (Figure 3C). A significantly better perfor-
mance was obtained in datasets with 1–10 known pertur-
bation targets (P-value = 7.82e–05 for datasets with 1–5
targets, and 3.40e–06 for 6–10), which represent 74% of all
datasets tested. The use of target-specific drugs or growth
factors is required to induce cellular transitions in a con-
trolled way, and these results demonstrate that our method
is particularly suited for such cases. As the majority of the
datasets analysed with our method concerned drug applica-
tion, but so few of the drug–target pairs had a known sign
(16% of all pairs), we could not comprehensively assess the
accuracy of the predicted signs. However, we did not ob-
serve a bias in our method towards the prediction of inhi-
bition or activation of signalling molecules (Supplementary
Figure S7).
There exist multiple other drug-perturbation gene ex-
pression datasets, for example the data generated for the
DREAM/NCI compound synergy challenge (34), which
are often used to benchmark methods that use gene expres-
sion data to predict cellular response to drugs (9,29). How-
ever, we could not estimate the gene expression probability
for those datasets because their microarray platforms are
incompatible with our method.
Properties of candidate signalling molecules
Next, we asked whether the sets of predicted candidate sig-
nalling molecules were related to direct perturbation targets
by analysing their functional and topological features. First,
the canonical signalling pathways extracted fromMetaCore
were tested for overrepresentation among candidate sig-
nalling molecules. We observed the enrichment of at least
one pathway in all datasets. Moreover, 89% of the times
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
served success rate, X = random success rate, horizontal error bars = 5th
and 95th percentiles of selected set size. The same fraction of ranks se-
lected corresponds to variable set sizes because of ties in the ranking. Sets
size range was removed from the random success rate points for clarity. (C)
Performance across datasets with increasing number of known perturba-
tion targets. Each point represents the random success rate for a dataset,
obtained by calculating how likely it is to find at least one perturbation
target in a random set of signalling molecules of same size as the one se-
lected by our method. The solid red lines represent the fraction of datasets
in each class, for which at least one of the targets was in the list of candi-
date signalling molecules selected by our method. Red dashed line: average
obtained performance across all classes (62%), blue dashed line: random
average performance (39%).
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Figure 4. Features of candidatemolecules vs. othermolecules. (A) Fraction
of datasets for which the enrichment of pathways in signalling molecules
selected either by our method or through differential expression, finds
a pathway containing perturbation targets (red), any other pathway (or-
ange), or no pathway significantly enriched. (B) Percentage of functional
terms mapping to the perturbation targets also enriched in the selected
molecule set, or the discarded molecule set. Whiskers indicate 1.5 * inter-
quantile range. The candidates have significant higher portion of enriched
functional terms shared with the perturbation targets (one-sidedWilcoxon
test, P-value = 6e–16, confidence interval = (0.1048031,Inf)). (C) The av-
erage distance from perturbation targets of candidates is smaller than the
average distance of non-candidates. Red bars = significant difference of
the distance distributions, grey bars= non-significant difference (Wilcoxon
test with 100 000 Monte Carlo replicates).
at least one of the pathways containing known targets was
enriched (Figure 4A). To further evaluate this result, we
also tested enrichment of MetaCore canonical pathways
in DEGs. 73.5% of the datasets showed some pathway en-
richment, but only in 35.2% of all datasets at least one
of the enriched pathways contained perturbation targets
(Figure 4A). This result indicates that also at signalling
pathway level, our method is far more effective in predict-
ing appropriate signalling perturbations than simply us-
ing DEGs. In addition, we collected all the GO biologi-
cal process terms associated with the perturbation targets
(target terms). Then, we calculated which GO terms were
enriched in the candidate signalling molecules and in the
non-candidate signalling molecules. The target terms were
more frequently overrepresented in the candidate signalling
molecules than in the non-candidate ones (P-value= 6e–16,
Figure 4B).
To investigate where the candidate signalling molecules
were located in the signalling network, we compared the
distribution of distances (minimum number of interactions
with same direction required to connect two nodes) from
selected candidate molecules to perturbation targets, and
from non-candidate molecules to targets. We found that
the distances were overall significantly shorter for candidate
molecules in 72% of the datasets, significantly longer in 2%
of the datasets, and comparable in 26% (Figure 4C). This
suggests that our method selects molecules that are not ran-
domly scattered in the signalling network, but are found in
the region where the applied perturbation acts.
In summary, candidate signalling molecules are more in-
volved in the same biological processes as the perturbation
targets than non-candidate molecules or DEGs. Addition-
ally, they are distributed in the signalling network in prox-
imity to perturbation targets. These results suggest that can-
didate signalling molecules are likely to induce the desired
cell state transition, and are novel candidates for further ex-
perimental validation.
Application to cell type transitions
In the context of regenerative medicine, the ability to in-
duce cellular conversions between different cell types would
allow to replace damaged tissues and organs. We tested
our methods on datasets where growth factors or drugs
were used to alter the cellular identity. These cases showed
larger GRNs compared to the CMap datasets (on aver-
age 37.5 versus 23 TFs), and overall better performance:
in all datasets the candidate signalling molecules contained
direct targets of the experimental perturbation (Table 2),
compared to the 60% success rate obtained across CMap
datasets.
Differentiation. In (35) the differentiation of human mes-
enchymal stromal cells to chondrocytes was obtained by
treatment with either BMP2 or TGF-3. Comparing the
gene expression profiles of the BMP2-treated cells to the
untreated ones, we predicted that the activation of both
BMP receptor 2 and TGFBR3 would induce the differ-
entiation, in accordance with the experimental evidence.
The activation or inhibition of other members of the TGF-
 protein superfamily, which is known to play an impor-
tant role in chondrocyte differentiation, was also predicted
when using both target gene expression profiles. We also
correctly predicted the activation of HDAC2 and the in-
hibition of HDAC9 for the differentiation of hematopoi-
etic stem/progenitor cells to erythroid and megakaryocytic
precursors (36); the application of EGF during differenti-
ation of neonatal keratinocytes to terminally differentiated
keratinocytes (37); and the activation of protein kinase G1
(PRKG1), a direct interactor of cAMP, as inducing hepato-
blasts differentiation towards a hepatocyte-like population
(38).
Cell activation and maintenance. The activation of pre-
adipocytes to primed pre-adipocytes can be obtained with
dexamethasone treatment (39), and in agreement with this
observation we predicted the activation of DAX1, a nu-
clear receptor for steroid hormones. Mesenchymal stem
cells can give rise to many cell types with different poten-
tial to establish a hematopoietic differentiation microenvi-
ronment. This particular competency is inhibited by treat-
ment with bFGF; the treatment with TGF-1 on the other
hand pushes the cells towards subendothelial murate cell
fate (40). Applying our method to bFGF-treated data, we
predicted the activation of subunits of the protein kinase
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Table 2. Results obtained on cell type transition examples. Ranks passing the 6% cut-off, which correspond to correct prediction, are reported in bold. Type:
D = differentiation, A = activation, M = maintenance, R = reprogramming. Cell types: MSC = mesenchymal stromal cells from the bone marrow; HSPC
= hematopoietic stem/progenitor cells; NHEK = normal human epidermal keratinocytes; HME = hematopoietic microenvironment in bone marrow
Type Initial cell type Perturbation Final cell type Ref.
Best
rank
Predicted direct
targets notes
D hMSC BMP2 chondrocytes (35) 10 ALK-2 TGF-3 targets
predicted: TGF-beta
receptor type III
(betaglycan)
Chordin inh
BMP receptor 2
Noggin inh
Ectodin inh
D TGF-3 38 Endoglin inh BMP2 targets
predicted : Chordin |
Noggin | Ectodin |
PTCH1 inh
D HSPC valproic acid Erythroid and
megakaryocytic
precursors
(36) 5 HDAC9 inh
HDAC2
D NHEK density-induced
differentiation,
treated with EGF
terminally
differentiated
keratinocytes
(37) 1 ErbB4
MSK1
D hepatoblasts cAMP hepatocyte-like cells (38) 143 Protein kinase G1
A pre-adipocytes dexamethasone primed
pre-adipocytes
(39) 93 DAX1
A mesenchymal
stem cells
bFGF non-HME cells (40) 24 Casein kinase II,
alpha chains
Casein kinase II,
alpha’ chain
(CSNK2A2)
A TGF-1 subendothelial mural
cell fate
103 Ubiquitin bFGF targets
predicted:
Syndecan-3 inh |
Casein kinase II,
alpha’ chain
(CSNK2A2) inh |
S100B inh
M hES-T3 activin A + bFGF - (41) 86 ALK-4 Protocols
comparison: MEF
feeder
M - 15 ALK-4 Protocols
comparison:
feeder-free
ALK-7
ALK-2 inh
R Mouse
embryonic
fibroblasts
CHIR99021 +
RepSox +
Forskolin +
valproic acid
cardiomyocytes (42) 166 RepSox:
JNK1(MAPK8) inh
R Adult
fibroblasts
SP600125 +
SB202190 +
Go6983
hMSC (43) 89 SP600125: p38beta
(MAPK11) inh;
JAK3 inh;
MSK1 inh
Go6983: cPKC
(conventional)
(opposite sign)
SB202190: p38beta
(MAPK11) inh;
p38alpha
(MAPK14) inh
CK2, known to bind and phosphorylate bFGF. When ap-
plied to TGF-1-treated data, our method did not predict
any direct target apart from ubiquitin, but it suggested the
inhibition of bFGF targets. Regardingmaintenance of stem
cells, in (41) the authors compared MEF feeder and feeder-
free protocols formaintenance of hESC-T3 in vitro, to treat-
ment with activin A in conditionedmedium. They observed
that self-renewal and pluripotency are preserved, but the
mRNA and miRNA expression profiles were significantly
different for the cells maintained with activinA.When com-
paring the activin A treatment with the other protocols, our
method correctly predicted the activation ofALK-4 (activin
A type IB receptor), activation of ALK-7, and inhibition of
ALK-2.
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Reprogramming. Cellular reprogramming is increasingly
obtained with chemical cocktails. We tested our method
on the direct conversion of mouse fibroblasts into car-
diomyocytes obtained in (42) with a combination of four
compounds (CHIR99021, RepSox, Forskolin and valproic
acid). Using data from primary cells, our method only pre-
dicted one direct target of RepSox. However, it predicted
the activation of Axin, which is a common target of GSK3,
a kinase that is inhibited by CHIR99021, and G-protein
alpha-s, one of Forskolin targets. Valproic acid, still, did
not have any target or target-first neighbor in the candi-
date signalling molecules. We also applied our method to
the conversion of primary human dermal fibroblasts into
mesenchymal stem cells. It was observed that the minimal
combination of SP600125, SB202190 and Go6983 is suffi-
cient to obtain MSC-like induced cells (43). Our method
correctly captured three direct targets of SP600125 (the in-
hibition of p38, JAK3 and MSK1) and two SB202190 tar-
gets (the inhibition of p38 in its  and  forms). Go6983
is an inhibitor of protein kinases C, for which our method
predicted instead the activation. This can arise from the fact
that multiple equally probable paths with opposing signs
can exist, but only one MPP is selected as representative of
the effect of a signalling molecule on an interface TFs.
In summary, our method consistently predicts signalling
perturbations that can induce cell type transitions. In ad-
dition, it can predict alternative ways of obtaining the same
cellular conversion, as observed in the differentiation of hu-
manmesenchymal stromal cells to chondrocytes, andmutu-
ally exclusive perturbations, as in the specification of suben-
dothelial murate cell fate in mesenchymal cells. This con-
firms that not only experimentally perturbed targets are
predicted, but also other selected signalling molecules are
biologically relevant. No other computational method is
known to be capable of systematically predict meaningful
signalling molecules for the induction of cell type transi-
tions.
Application to disease treatment
Finally, we applied this method to the prediction of sig-
nalling molecules for disease treatment. In particular, we
analysed cirrhotic versus healthy rat liver in order to induce
the shift in the gene expression state of the diseased tissue
towards the healthy state (Figure 5A). Currently, the ther-
apeutic prospects for cirrhosis patients are limited to liver
transplantation and, therefore, there is an urgent need to
develop new therapeutic strategies. Cirrhosis was induced
in male Wistar rats with CCl4 treatment, and RNA from
the complete livers was extracted and quantified through
microarray experiments. The gene expression profile of the
desired healthy liver state was obtained from publicly avail-
able data (see Materials and Methods). The GRN built by
our method consisted of 26 TFs (Figure 5B). After in silico
perturbation of the 106 interface TFs connecting this GRN
to the signalling network, we identified 10 TFs that were
present in the BPCs (Figure 5C). Altogether, the BPCs were
predicted to change the state of 19 GRN-TFs (Figure 5B).
The overall ranking of signalling molecules prioritized
many proteins known to be involved in different aspects of
liver fibrosis, fatty liver disease, cirrhosis, and hepatocellular
carcinoma. In particular, the inhibition of fibrosis-related
proteins was predicted (e.g. CHIP, AP-1, CBP, MDM2),
along with the activation of ESR2, known for its antifibro-
genic effects (44), and the inhibition of MMPs responsible
for matrix remodelling. Multiple interleukins and proteins
related to innate immune response in liver cirrhosis (45)
were also selected as candidates. Another biological pro-
cess emerging in our predictions is angiopoietins signalling,
a key pathway in blood vessel normalization. Angiopoietin
1 (Ang1)-Tie2 signalling stabilizes blood vessels, Angiopoi-
etin 2 (Ang2) on the other hand is a context-dependent
antagonist of Ang1 and decreases its stabilizing effect (46)
giving rise to immature blood vessels. Cirrhotic conditions
are characterized by higher expression and activity of Ang2
than healthy conditions, resulting in the loss of blood ves-
sels stability. In this regard, the activation of angiopoietins
receptor Tie2 ranked 24th among all signalling molecules,
and our method also predicted the activation of Angiopoi-
etin 1 and 4 and the inhibition ofAngiopoietin 2 and 3 (Sup-
plementary Table S3). Our model predicted that the activa-
tion of Tie2 would activate the interface TFs SP1 and ETS1,
and inhibit GCR, STAT5A and B, ESR1, and PU.1 (Sup-
plementary Figure S8), inducing a GRN state that partially
matches the healthy liver state (Figure 5B). To test this pre-
diction, we generated gene expression data from the whole
liver of cirrhotic rats treated with CVX-060, an inhibitor of
Ang2 which induces Tie2 activation, and observed that the
GRN-TFs EBF1, EGR3, PRDM1, RUNX3, SP7, RARG
and TP63 were indeed reverted to the healthy state (Figure
5B). EGR3 and RUNX3 have been implicated in the patho-
physiology of fibrosis and liver development. EGR3 is a
pro-inflammatory and immunogenic factor, its overexpres-
sion is sufficient to stimulate fibrosis, whereas suppression
of Egr-3 activity in deficient mice correlated with the atten-
uation of the TGF- signalling and consequently of fibro-
genesis (47). EGR3 is also an essential effector of VEGF-
mediated functions leading to angiogenesis (48). Runx3 is
mostly expressed in the liver during the embryonic develop-
ment and is a regulator of fetal hematopoiesis (49). Runx3
knockout mice died within 24 h after birth showing organo-
genesis defects in lung and liver. In addition, the absence
of Runx3 activity was associated with excessive intrahepatic
angiogenesis, suggesting that the physiological function of
this TF in the liver is mainly embryonic (50). RA signalling
through RARG has been shown to reverse hepatic stellate
cell activation and fibrosis (51), SP7 and TP63 have been
previously implicated in the regulation of VEGF-mediated
angiogenesis, while PRDM1 and EBF1 have no clear con-
nection with angiogenesis or cirrhosis reported to this date
and could be novel therapeutic targets.
Next, we constructed a GRN for the treated gene ex-
pression profile, and compared it with the disease GRN.
The treated GRN had a similar size to the disease GRN
(30 TFs), and shared 14 TFs with it. However, the 12
TFs that were exclusively present in the disease network
were localized in network-specific modules that contained
TFs playing a major role in vascular growth, including
the disease-specific TFs TP63, EGR3, RUNX3 and SP7,
discussed above (Supplementary Figure S8). On the other
hand, modules shared between the disease- and the treated
GRNs did not contain TFs associated with angiogenesis.
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Figure 5. Application to cirrhotic model in rat. (A) Our method was applied to gene expression data of whole liver from cirrhotic and healthy rats,
respectively generated in this study and obtained from public repositories. The activation of the angiopoietins receptor Tie2 was predicted as potential
signalling perturbation able to convert the disease towards the healthy phenotype. Cirrhotic rats were treated with the specific Tie2 activator CVX-060,
and gene expression was profiled again and compared with the data corresponding to healthy animals. (B) Boolean state of GRN TFs as measured in
cirrhotic, healthy, and CVX-060 treated samples. The ideal perturbation state refers to the state that the GRN TF can reach if any of the BPCs is applied.
The predicted CVX-060 treated state is the state the GRN-TFs can have if the BPCs composed only of interface TF states induced by the activation of
Tie2, according to our predictions (using the correlation-based MPPs). Green background is used when a state is matching the desired healthy state. (C)
Interface TFs present in the best in silico perturbations and their relative probability of inducing the desired changes on the GRN. +: the activation of the
interface TFs acts on the GRN; –: its inhibition affects the GRN. The two states are not mutually exclusive, see c-Rel (NF-kB subunit).
This confirms that the activation of Tie2 specifically tar-
geted the transcriptional regulators of angiogenesis, and re-
verted their gene expression state to the healthy counter-
part.
Taken together, this experimental study provides insights
into the molecular changes during the inhibition of Ang2
with CVX-060 in cirrhotic rat liver. Importantly, it com-
plements the previous functional study where inhibition
of Ang2 and activation of the Tie2 signalling have been
demonstrated to improve the normalization of intrahepatic
blood vessels and to decrease the liver inflammatory infil-
trate, and thus an effective treatment for liver fibrosis in
cirrhotic rats (52). As activation of Tie2 only partially re-
verts the disease phenotype, a combination of candidates
involved in different aspects of the disease is probably neces-
sary to obtain the complete switch towards a healthy expres-
sion profile. In this context, endothelin inhibition is another
predicted candidate (ranking 17th overall, see Supplemen-
tary Table S3) that plays an important pathological role in
cirrhotic livers through a different mechanism, fibrogenesis
induction. Independent studies have convincingly described
that an overexpression of endothelin-1 is associatedwith the
pathological activation of hepatic stellate cells, which are
the major source of collagen expression in the liver, and in-
trahepatic vascular dysfunction through exacerbated vaso-
constriction (26).
Comparison with existing methods
No method similar to ours in terms of application or mod-
elling strategy exists to date. Therefore, we compared our
method to computational tools that differ from ours by
approach and application, but which are widely used to
analyse signalling perturbations using gene expression data.
Connectivity Map (28) uses gene expression similarity be-
tween a compendium of known perturbations and a query
signature (list of up- and down-regulated genes) to rank
small molecules, drugs and gene perturbations. SPIA (27)
scores signalling pathways by their enrichment in DEGs,
while also taking into account their topology. We applied
both Connectivity Map and SPIA to the 219 datasets con-
sidered in our analysis, and obtained results for respectively
136 and 211 datasets where the tools could be applied and
the prediction of the experimental perturbation was possi-
ble. We then focused on the 135 datasets that obtained pre-
dictions from all three methods (ours, Connectivity Map
and SPIA). (Figure 6A, Supplementary Table S4). SPIA
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Figure 6. Comparison with previously published methods. (A) Perfor-
mance of our method, Connectivity Map (CMap) and SPIA on datasets
that could be analysed with the three methods (upper panel), and on cell
type transition cases (lower panel). The number of cases in which the pre-
dictions of one or more methods were correct are reported. (B) Perfor-
mance of DeMAND and our method on the eight compound perturba-
tion datasets that could be analysed with both. Both methods correctly
predicted direct perturbation targets for all datasets except (S)-equol and
thapsigargin.
correctly predicted KEGG pathways containing direct per-
turbation targets in only 33% of such datasets. Connectiv-
ity Map in turn correctly predicted either the experimen-
tal perturbation, its gene targets, or drugs regulating the
same targets, in 64% of the datasets, and our method ob-
tained correct signalling molecules in 74% of the datasets.
While Connectivity Map has an overall success rate similar
to our method, it was not very successful in cell type tran-
sition datasets, only retrieving correct perturbations in four
of them (Figure 6A). SPIA showed a performance similar to
Connectivity Map in these cases. This result suggests a su-
perior performance of our method in predicting novel per-
turbations, which are not present in the Connectivity Map
compendium.
We also compared our method to DeMAND (29), a
GRN-based tool aiming at identifying compounds mode
of action using gene expression profiles and context-specific
regulatory networks. Considering each gene G and the list
of genes that it can regulate, called regulon, DeMAND
scores each gene G based on how significantly the expres-
sion of its regulon is dysregulated following drug applica-
tion. As it requires at least six samples for each condition
to give reliable results, DeMAND could not be applied to
the datasets analysed with our method, and we could not
assess its suitability for the induction of cell fate transi-
tions. Instead, we tested our method on the compound per-
turbation datasets that were used for DeMAND’s evalua-
tion. We obtained candidates in nine datasets, however in
one case the perturbation targets were absent from the sig-
nalling network used in ourmethod, and therefore their pre-
diction was not possible. Both our method and DeMAND
obtained correct predictions in six of the remaining eight
datasets (75%) (Figure 6B, Supplementary Table S4). Aside
from obtaining comparable performance to DeMAND us-
ing substantially less data, our method explicitly predicts
the activation or the inhibition of signalling molecules, and
correctly reported signs in 5/6 datasets, thus overcoming an
important limitation of DeMAND.
DISCUSSION
Here we have introduced the first general method, to our
knowledge, which uses gene expression data to predict sig-
nalling perturbations that can induce the transition from an
initial to a desired cellular phenotype. For this purpose, sin-
gle signalling molecules are prioritized according to their
probability of specifically acting on the interface TFs that
are most likely to trigger the shift from the initial to the re-
quired GRN state.
Our approach differs conceptually from previously pub-
lished studies since it constitutes a general methodology
that integrates signalling and gene regulatory networks by
considering transitions between GRN states corresponding
to the initial and target cellular phenotypes. On the con-
trary, other GRN-based approaches solely rely on GRN
topology, and therefore ignore collective changes in TF ex-
pression induced by the signalling cues. Furthermore, our
method was more successful than GRN-free methods in
predicting signalling targets for cellular conversions, and
showed similar performance compared to another GRN-
based method (DeMAND), which requires higher amount
of data. Importantly, the pathways predicted by thismethod
to be involved in signal transduction were supported by
changes in phosphorylation state (when data was available),
indicating that gene expression alone can be reasonably
used to analyse signalling processes in the absence of phos-
phoproteomics and perturbation data.
Results show that our method is able to consistently iden-
tify signalling targets of experimentally validated pertur-
bations, and novel candidates with potential to induce de-
sired cellular transitions. In particular, our method cor-
rectly predicted experimentally validated signalling targets
in the analysed cell type transition examples, including cel-
lular differentiation, reprogramming. Further, we applied
our method to a liver cirrhosis model in rat to predict sig-
nalling molecules whose perturbations could revert the dis-
ease phenotype. Experimental perturbation of the predicted
angiopoietins receptor (Tie2) induced desired changes in
the gene expression of key TFs involved in fibrosis and an-
giogenesis.
An important limitation of ourmethod is that it only pre-
dicts single signalling molecules, whereas combinations of
these molecules could improve the efficiency of cellular con-
version. In this regard, this method could be extended to the
prediction of combinations of signalling molecules in order
to take into account the combinatorial effect ofmultiple sig-
nalling molecules, which could be synergistic or redundant.
In conclusion, we believe that this method represents a
general tool that can guide the identification of signalling
molecules for the induction of desired cellular transitions,
such as the reversal of disease phenotypes and the induction
of cell differentiation or reprogramming, with perspective
applications to disease treatment and regenerativemedicine.
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DATA AVAILABILITY
The method was implemented in Matlab and R. It is
available as a Snakemake pipeline (53) with all nec-
essary datasets at: https://git-r3lab.uni.lu/gaia.zaffaroni/
INCanTeSIMO. All microarray data generated is available
in GEO under accession number GSE122822.
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Supplementary Data are available at NAR Online.
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